57 related articles for article (PubMed ID: 35316225)
1. Aspirin Use and the Risk of Hepatocellular Carcinoma: A Meta-analysis.
Wang Y; Wang M; Liu C; Wang W; Shi J; Dang S
J Clin Gastroenterol; 2022 Aug; 56(7):e293-e302. PubMed ID: 35316225
[TBL] [Abstract][Full Text] [Related]
2. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B.
Lee CH; Lee YB; Moon H; Chung JW; Cho EJ; Lee JH; Yu SJ; Kim YJ; Lee J; Yoon JH
Aliment Pharmacol Ther; 2023 Oct; 58(7):704-714. PubMed ID: 37461332
[TBL] [Abstract][Full Text] [Related]
3. Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Memel ZN; Arvind A; Moninuola O; Philpotts L; Chung RT; Corey KE; Simon TG
Hepatol Commun; 2021 Jan; 5(1):133-143. PubMed ID: 33437907
[TBL] [Abstract][Full Text] [Related]
4. Aspirin in Patients with Viral Hepatitis: Systematic Review and Meta-Analysis of Observational Studies.
Bian W; Bian W; Li Q; Li Y
J Gastrointest Cancer; 2024 Apr; ():. PubMed ID: 38557825
[TBL] [Abstract][Full Text] [Related]
5. Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver cancer.
Xia H; Hui KM
Cell Death Dis; 2017 Oct; 8(10):e3112. PubMed ID: 29022914
[No Abstract] [Full Text] [Related]
6. Daily aspirin associated with a reduced risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a population-based cohort study.
Lee TY; Hsu YC; Ho HJ; Lin JT; Chen YJ; Wu CY
EClinicalMedicine; 2023 Jul; 61():102065. PubMed ID: 37434747
[TBL] [Abstract][Full Text] [Related]
7. The relationship between aspirin consumption and hepatocellular carcinoma: a systematic review and meta-analysis.
Wang S; Zuo L; Lin Z; Yang Z; Chen R; Xu Y
Eur J Med Res; 2023 Jul; 28(1):226. PubMed ID: 37422691
[TBL] [Abstract][Full Text] [Related]
8. Aspirin Use and the Risk of Hepatocellular Carcinoma: A Meta-analysis.
Liao KF; Lai SW
J Clin Gastroenterol; 2023 Jul; 57(6):640-641. PubMed ID: 37079875
[No Abstract] [Full Text] [Related]
9. Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis.
Ma S; Qu G; Sun C; Liu H; Jiang Y; Li N; Wu B; Gao J; Feng L; Xie P; Xia W; Kim NH; Lowe S; Bentley R; Zhu Y; Zhou Q; Sun Y
Eur J Clin Pharmacol; 2023 Jan; 79(1):39-61. PubMed ID: 36334108
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis.
Huang DQ; Tan DJH; Ng CH; Amangurbanova M; Sutter N; Lin Tay PW; Lim WH; Yong JN; Tang A; Syn N; Muthiah MD; Tan EXX; Dave S; Tay B; Majzoub AM; Gerberi D; Kim BK; Loomba R
Clin Gastroenterol Hepatol; 2023 May; 21(5):1169-1177. PubMed ID: 35940513
[TBL] [Abstract][Full Text] [Related]
11. The relationship between nonsteroidal anti-inflammatory drugs and cancer incidence: An umbrella review.
Wang P; Chen B; Huang Y; Li J; Cao D; Chen Z; Li J; Ran B; Yang J; Wang R; Wei Q; Dong Q; Liu L
Heliyon; 2024 Jan; 10(2):e23203. PubMed ID: 38312641
[TBL] [Abstract][Full Text] [Related]
12. Hepatoprotective effects of aspirin on diethylnitrosamine-induced hepatocellular carcinoma in rats by reducing inflammation levels and PD-L1 expression.
Wang Y; Wang M; Liu C; Hao M; Wang W; Li Y; Shi J; Zhang X; Dang S
Sci Rep; 2023 Dec; 13(1):21362. PubMed ID: 38049630
[TBL] [Abstract][Full Text] [Related]
13. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy.
Singal AG; Kanwal F; Llovet JM
Nat Rev Clin Oncol; 2023 Dec; 20(12):864-884. PubMed ID: 37884736
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Aspirin Use on Incident Hepatocellular Carcinoma-An Updated Systematic Review and Meta-Analysis.
Abdelmalak J; Tan N; Con D; Eslick G; Majeed A; Kemp W; Roberts SK
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444628
[TBL] [Abstract][Full Text] [Related]
15. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Cernea S; Onișor D
World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.
Zeng RW; Yong JN; Tan DJH; Fu CE; Lim WH; Xiao J; Chan KE; Tan C; Goh XL; Chee D; Syn N; Tan EX; Muthiah MD; Ng CH; Tamaki N; Lee SW; Kim BK; Nguyen MH; Loomba R; Huang DQ
Aliment Pharmacol Ther; 2023 Mar; 57(6):600-609. PubMed ID: 36625733
[TBL] [Abstract][Full Text] [Related]
17. Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics.
Lai H; Liu Y; Wu J; Cai J; Jie H; Xu Y; Deng S
Front Pharmacol; 2022; 13():1078766. PubMed ID: 36545311
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response.
Minami Y; Aoki T; Chishina H; Takita M; Hagiwara S; Ida H; Ueshima K; Nishida N; Kudo M
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230773
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
